Drug research
0.5 mg ranibizumab
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)NCT04757610 | Opthea Limited | Phase 3 | Terminated | 2025-03-31Actual |
Regulatory dates and decisions
| No regulatory events published here yet.Events appear after automated checks of their supporting sources. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |